CR8439A - Metodo para mejorar la eficacia de drogas terapeuticas radio rotuladas - Google Patents

Metodo para mejorar la eficacia de drogas terapeuticas radio rotuladas

Info

Publication number
CR8439A
CR8439A CR8439A CR8439A CR8439A CR 8439 A CR8439 A CR 8439A CR 8439 A CR8439 A CR 8439A CR 8439 A CR8439 A CR 8439A CR 8439 A CR8439 A CR 8439A
Authority
CR
Costa Rica
Prior art keywords
radio
improving
effectiveness
labeled
therapeutic drugs
Prior art date
Application number
CR8439A
Other languages
English (en)
Inventor
Werner Krause
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CR8439A publication Critical patent/CR8439A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se dan a conocer drogas radiorotuladas y metodos para mejorar su eficacia mediante el uso de un radiosensibilizador tal que el radiosensibilizador tanto forma parte de la droga radiorotulada mediante el acople directo del rediosensibilizador a la droga radiorotulada como produciendo una mezcla de la droga radiorotulada y un analogo de la droga con el radiosensibilizador acoplado a la droga en lugar del radiorotulo
CR8439A 2003-12-11 2006-06-07 Metodo para mejorar la eficacia de drogas terapeuticas radio rotuladas CR8439A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52847303P 2003-12-11 2003-12-11

Publications (1)

Publication Number Publication Date
CR8439A true CR8439A (es) 2006-12-07

Family

ID=34676848

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8439A CR8439A (es) 2003-12-11 2006-06-07 Metodo para mejorar la eficacia de drogas terapeuticas radio rotuladas

Country Status (14)

Country Link
EP (1) EP1691838A2 (es)
JP (1) JP2007528874A (es)
KR (1) KR20060118542A (es)
CN (1) CN101031319A (es)
AU (1) AU2004296621A1 (es)
BR (1) BRPI0417517A (es)
CA (1) CA2546057A1 (es)
CR (1) CR8439A (es)
EC (1) ECSP066618A (es)
IL (1) IL175674A0 (es)
MX (1) MXPA06006683A (es)
NO (1) NO20063207L (es)
RU (1) RU2006124510A (es)
WO (1) WO2005056058A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
CN106975078B (zh) * 2017-03-31 2020-11-10 国家纳米科学中心 一种包含多钨酸钆的纳米材料作为增敏剂的用途
WO2024013272A1 (en) * 2022-07-13 2024-01-18 Universite De Montpellier Combined therapy with nanoparticles and radiopharmaceuticals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022404A1 (es) * 1999-01-25 2002-09-04 Photogen Inc Metodo y agentes para la terapia de radiacion mejorada
AU2001249608A1 (en) * 2000-03-28 2001-10-08 Beth Israel Deaconess Medical Center Bladder cancer-specific peptides for diagnosis and therapy
EA007388B1 (ru) * 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн Модифицированные антитела и способы применения
EP1534336A4 (en) * 2002-08-15 2005-12-14 Human Genome Sciences Inc ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS

Also Published As

Publication number Publication date
AU2004296621A1 (en) 2005-06-23
MXPA06006683A (es) 2006-08-11
RU2006124510A (ru) 2008-01-20
ECSP066618A (es) 2006-10-25
IL175674A0 (en) 2006-09-05
KR20060118542A (ko) 2006-11-23
NO20063207L (no) 2006-07-10
CA2546057A1 (en) 2005-06-23
BRPI0417517A (pt) 2007-03-06
WO2005056058A3 (en) 2006-04-13
JP2007528874A (ja) 2007-10-18
WO2005056058A2 (en) 2005-06-23
EP1691838A2 (en) 2006-08-23
CN101031319A (zh) 2007-09-05

Similar Documents

Publication Publication Date Title
GT200300245A (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
CL2015001891A1 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014).
DOP2017000177A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer
MY157661A (en) Bendamustine pharmaceutical compositions
AR048833A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
HN2003000039A (es) 2-(PIRIMIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONAS
MX2007010996A (es) Nuevas composiciones de liposomas.
DE602005014671D1 (de) Tricyclische delta-opioid-modulatoren
EA200600433A1 (ru) Сопряжённые гетероциклические соединения
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
PA8654601A1 (es) Agentes citotoxicos que comprenden taxanos nuevos
GT200500127A (es) Composiciones y metodos para el tratamiento de trastorno disforico premenstrual
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
AR032293A1 (es) Estuche farmaceutico
MX2008008413A (es) Composicion farmaceutica para el tratamiento de las enfermedades de las uñas.
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
CR8439A (es) Metodo para mejorar la eficacia de drogas terapeuticas radio rotuladas
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
DK1699480T3 (da) Allogent terapeutisk tumormiddel
NI200800216A (es) Uso de compuestos peptídicos de tpo y composiciones farmacéuticas en el tratamiento de la anemia
Marcellin et al. Viral hepatitis: impressive advances but still a long way to eradication of the disease
PA8571401A1 (es) Imidazolinilmetil aralquilsulfonamidas
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana